PURDUE

SAFETY DATA SHEET

Issue Date 30-Jul-2008 Revision Date 16-Nov-2016 Version 3

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION

Product Name Dilaudid® (hydromorphone hydrochloride) Tablets C-II

Synonyms Dilaudid[®] 2, 4, 8 mg Tablets, dihydromorphinone hydrochloride

Other Information This is a controlled substance under Schedule II of the Controlled Substances Act.

Recommended Use Opioid analgesic

Manufacturer Address Purdue Pharma L.P.

One Stamford Forum 201 Tresser Boulevard

Stamford, Connecticut 06901-3431

(888) 726-7535

24 Hour Emergency Phone Number Chemtrec (800) 424-9300

For all international transportation emergencies, call Chemtrec collect at (703) 527-3887.

2. HAZARDS IDENTIFICATION

Drugs when in solid final form (e.g. capsules, tablets or pills) are considered exempt under the criteria of the Federal OSHA Hazard Communication Standard, 29 CFR 1910.1200. However, in an industrial setting where a component's occupational exposure limits may be surpassed, they can be considered hazardous.

Emergency Overview				
Appearance Tablet	Physical state Solid	Odor Odorless		

Hazards Not Otherwise Classified (HNOC)

Not Applicable.

Other Information

Acute oral toxicity for hydromorphone hydrochloride ranged from 50-300 mg/kg.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Chemical Name	CAS No	Weight %
Hydromorphone hydrochloride	71-68-1	1-10

4	FIRST	MF	SURES
	111/01		

First aid measures

Eye contact In case of eye contact, immediately flush eyes with fresh water for at least 15 minutes while

holding the eyelids open. Remove contact lenses if worn. Get medical attention if irritation

persists.

Skin contact In case of contact, remove contaminated clothing. Immediately flush skin with copious

amounts of water for at least 15 minutes. Obtain medical attention if skin reaction occurs.

In case of inhalation, remove to fresh air. If not breathing, provide artificial respiration. If

breathing is difficult, administer oxygen. Seek medical attention immediately.

Ingestion In case of accidental ingestion, wash out mouth with copious amounts of water. Seek

medical attention immediately. Do not induce vomiting unless directed by medical

personnel. Never give anything by mouth to an unconscious person.

Self-protection of the first aiderDo not use mouth-to-mouth method if victim ingested or inhaled the substance; give

artificial respiration with the aid of a pocket mask equipped with a one-way valve or other

proper respiratory medical device.

Most important symptoms and effects, both acute and delayed

Symptoms Overdose may cause dizziness, euphoria, flushing, itching, hypotension, pinpoint pupils,

nausea/vomiting, constipation, and reduced urination. Serious overdose produces respiratory depression, extreme somnolence, stupor or coma, skeletal muscle flaccidity, cold and clammy skin, bradycardia, and hypotension. Severe overdose produces apnea,

circulatory collapse, cardiac arrest, and death.

Indication of any immediate medical attention and special treatment needed

Note to physicians Hydromorphone hydrochloride is a pure opioid agonist with an analgesic potency about 8

times that of morphine. Naloxone is a specific antidote against respiratory depression from opioid overdose. Opioid antagonists should not be administered in the absence of clinically significant respiratory or circulatory depression secondary to hydromorphone hydrochloride

overdose.

In cases of overdose, primary attention should be given to the re-establishment of a patent airway and institution of assisted or controlled ventilation. Supportive measures (including oxygen and vasopressors) should be employed in the management of circulatory shock and

pulmonary edema accompanying overdose as indicated.

5. FIRE-FIGHTING MEASURES

Suitable Extinguishing Media

Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

Unsuitable Extinguishing Media No information available.

Specific hazards arising from the chemical

Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.

Explosion Data

Sensitivity to Mechanical Impact None. Sensitivity to Static Discharge None.

Protective equipment and precautions for firefighters

As in any fire, wear self-contained breathing apparatus pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures

Personal precautions Evacuate personnel to safe areas. Use personal protection recommended in Section 8.

Other Information Dust deposits should not be allowed to accumulate on surfaces, as these may form an

explosive mixture if they are released into the atmosphere in sufficient concentration. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Nonsparking

tools should be used.

Environmental precautions

Environmental precautions See section 12 for additional Ecological Information.

Methods and material for containment and cleaning up

Methods for containment Prevent further leakage or spillage if safe to do so. Prevent dust cloud.

Methods for cleaning up Pick up and transfer to properly labeled containers.

7. HANDLING AND STORAGE

Precautions for safe handling

Advice on safe handling Avoid contact with skin, eyes or clothing. Wash thoroughly after handling. Wash

contaminated clothing before reuse. Avoid generation of dust and accumulation. Routine housekeeping should be instituted to ensure that dusts do not accumulate on surfaces.

Conditions for safe storage, including any incompatibilities

Storage conditions Hydromorphone hydrochloride is a Schedule II Controlled Substance and requires DEA-

compliant storage. Keep containers tightly closed. Protect from light. To maintain potency, store at 25°C (77°F) and control temperature excursions to between 15-30°C (59-86°F).

Incompatible materials Strong oxidizers, acids, bases.

Oxidizing materials will increase the risk of fire and explosion (e.g., potassium perchlorate,

potassium nitrate).

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Exposure Guidelines

Chemical Name	Performance-Based Exposure Band (PBEB)	Company OEG (ug/m³)
Hydromorphone hydrochloride	None	2

Engineering Controls Handle material under adequate ventilation (e.g., chemical fume hood, vented balance

enclosure [VBE]). Keep container tightly closed. Minimize the amount of material handled

at any one time

Individual Protection Measures (Personal Protective Equipment)

Eye/face protection None required for consumer use. In laboratory or industrial settings, safety glasses with

side shields are recommended. The use of goggles or full face protection may be required depending on the industrial exposure setting or possibility of splashing. Contact a health

and safety professional for specific information.

Skin and body protection

None required for consumer use. In laboratory or industrial settings, gloves and lab coats are recommended. Contact a health and safety professional for specific information.

Respiratory protection

Respirators may be required for certain laboratory and manufacturing tasks if engineering controls do not maintain airborne concentrations below recommended exposure limits (where applicable) or to an acceptable level (where the exposure limits have not been established). Workplace risk assessments should be completed before specifying and implementing respirator usage. In the United States of America, if respirators are used, they are to be NIOSH-approved and part of a respiratory protection program instituted to assure compliance with OSHA Standard 29 CFR 1910.134. Contact a health and safety professional or manufacturer for specific information.

General Hygiene Considerations

Handle in accordance with good industrial hygiene and safety practice.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical and Chemical Properties

Physical stateSolidAppearanceTabletOdorOdorless

Color Orange (2 mg), yellow (4 mg), white (8 mg)

Odor threshold No information available.

<u>Property</u> <u>Values</u>

pH No information available.

Melting point / melting range 305-315 °C

Boiling point / boiling range
Flash point
Evaporation rate

No information available.
No information available.
No information available.

Flammability (solid, gas)

Flammability limits in air

No information available.
No information available.

Upper flammability limits
Lower flammability limits

Vapor pressureNo information available.Vapor densityNo information available.Specific gravityNo information available.Water solubility1 in 3 parts of waterSolubility in other solventsNo information available.Partition coefficient (n-No information available.

octanol/water)

Autoignition temperature
Decomposition temperature
Kinematic viscosity
Dynamic viscosity
Explosive properties
No information available.

Other Information

Softening point
Molecular weight
VOC content; (%)
Density
No information available.

pKa 8.1 @ 25 °C

Remarks • Method

decomposes; hydromorphone hydrochloride

10. STABILITY AND REACTIVITY

Chemical stability Low stability hazard expected at normal operating temperatures.

Possibility of hazardous reactions No information available.

Hazardous polymerization

Hazardous polymerization does not occur.

Conditions to avoid

Static charge, sparks, generation of dust, and temperatures above 200°C.

Incompatible materials Strong oxidizers, acids, bases.

Oxidizing materials will increase the risk of fire and explosion (e.g., potassium perchlorate,

potassium nitrate).

Hazardous decomposition products None known based on available information.

11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Product Information No data available.

Inhalation No data available.

Eye contact No data available.

Skin contact No data available.

Ingestion No data available.

Chemical Name	Oral LD50	Dermal LD50	Inhalation LC50
Hydromorphone hydrochloride	51 mg/kg (Rat)	-	-

Information on toxicological effects

Symptoms Overdose may cause dizziness, euphoria, flushing, itching, hypotension, pinpoint pupils,

nausea/vomiting, constipation, and reduced urination. Serious overdose produces respiratory depression, extreme somnolence, stupor or coma, skeletal muscle flaccidity, cold and clammy skin, bradycardia, and hypotension. Severe overdose produces apnea,

circulatory collapse, cardiac arrest, and death.

Skin corrosion/irritation Not a skin irritant.

Sensitization Hydromorphone in a patch is negative in skin sensitizing test.

Delayed and immediate effects as well as chronic effects from short and long-term exposure

Germ cell mutagenicity Hydromorphone was not genotoxic in the Ames bacterial mutagenicity test, in the

chromosome aberration assay in human lymphocytes, or in the mouse bone marrow

micronucleus test.

Carcinogenicity Not listed by IARC, NTP or US OSHA.

Reproductive toxicity

Developmental Toxicity Embryo-fetal toxicity effects were not produced following administration of hydromorphone

hydrochloride at oral doses up to 7 mg/kg/day in rats from day 6 to day 17 of gestation and

up to 25 mg/kg/day in rabbits from day 6 to day 20 of gestation.

Teratogenicity Teratogenic effects were not produced following administration of hydromorphone

hydrochloride at oral doses up to 7 mg/kg/day in rats from day 6 to day 17 of gestation and

up to 25 mg/kg/day in rabbits from day 6 to day 20 of gestation.

Administration to Syrian hamsters shows that hydromorphone is teratogenic at a dose of 20

mg/kg. However, in these studies, profound sedation and hypoxia/hypercarbia in pregnant animals is believed to be the cause of the teratogenic effects, not the direct effect of

hydromorphone hydrochloide on the fetus.

STOT-single exposure No information available.

STOT-repeated exposure No information available.

Aspiration hazard No information available.

Acute toxicity Acute oral toxicity for hydromorphone hydrochloride ranged from 50-300 mg/kg.

12. ECOLOGICAL INFORMATION

Ecotoxicity

Chemical Name	Algae/aquatic plants	Fish	Toxicity to microorganisms	Crustacea
Hydromorphone		Chronic NOEL 5.4 mg/L		
hydrochloride		(Fathead minnow)		

Persistence and degradability No information available.

Bioaccumulation No information available.

Chemical Name	Partition coefficient
Hydromorphone hydrochloride	-0.37

Other adverse effects No information available.

13. DISPOSAL CONSIDERATIONS

Waste treatment methods

Disposal of wastes Disposal should be in accordance with applicable regional, national, and local laws, and

regulations.

Contaminated Packaging Do not reuse container.

14. TRANSPORT INFORMATION

DOT Not regulated.

IATA Not regulated.

15. REGULATORY INFORMATION

Hydromorphone hydrochloride preparations are subject to control under the US Federal Controlled Substances Act of 1970 as schedule II (C-II) drugs.

International Inventories

TSCA Not determined.
DSL Not determined.

Legend:

TSCA - United States Toxic Substances Control Act Section 8 (b) Inventory DSL/NDSL - Canadian Domestic Substances List/Non-Domestic Substances List

US Federal Regulations

SARA 313

Section 313 of Title III of the Superfund Amendments and Reauthorization Act of 1986 (SARA). This product does not contain any chemicals which are subject to the reporting requirements of the Act and Title 40 of the Code of Federal Regulations, Part 372.

SARA 311/312 Hazard Categories

Acute Health HazardNoChronic Health HazardNoFire HazardNoSudden Release of Pressure HazardNoReactive HazardNo

CWA (Clean Water Act)

This product does not contain any substances regulated as pollutants pursuant to the Clean Water Act (40 CFR 122.21 and 40 CFR 122.42).

CERCLA

This material, as supplied, does not contain any substances regulated as hazardous substances under the Comprehensive Environmental Response Compensation and Liability Act (CERCLA) (40 CFR 302) or the Superfund Amendments and Reauthorization Act (SARA) (40 CFR 355). There may be specific reporting requirements at the local, regional, or state level pertaining to releases of this material.

US State Regulations

California Proposition 65

This product does not contain any Proposition 65 chemicals.

US State Right-to-Know Regulations

US EPA Label Information

EPA Pesticide Registration Number Not Applicable.

16. OTHER INFORMATION

NFPA Health Hazards 0 Flammability 0 Instability 0 Physical and Chemical Properties HMIS Health Hazards 0 Flammability 0 Physical Hazards 0 Personal protection X

General Information Refer to NFPA 654, Standard for the Prevention of Fire and Dust Explosions from the

Manufacturing, Processing, and Handling of Combustible Particulate Solids, for Safe

Handling.

Prepared By This SDS was prepared by the Environmental, Health, and Safety & Toxicology

Departments of Purdue Pharma L.P.

Issue Date30-Jul-2008Revision Date16-Nov-2016

Revision Note (M)SDS sections updated. 2. 8. 11.

Disclaimer

The information contained in this Safety Data Sheet is believed to be accurate and represents the best information available at the time of preparation. However, no warranty, express or implied, with respect to such information, is made. The data in this Safety Data Sheet relate only to the specific material designated herein and do not relate to use in

Revision	Data	16-Nov	2016
Revision	Date	10-1104	-2010

combination with any other material. The data in this Safety Data Sheet are subject to revision as additional knowledge and experience are gained.

End of Safety Data Sheet
